Chronic hepatitis B: Is it time for expanded antiviral treatment?

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 3

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Virol. Sep 25, 2025; 14(3): 103347
Published online Sep 25, 2025. doi: 10.5501/wjv.v14.i3.103347

Table 10 Highlights the chemotherapeutic drugs associated with a high risk of occult hepatitis B virus infection reactivation

Drug	Mechanism of action	Ref.
Rituximab	Anti-CD20 monoclonal antibody	[111-113]
Rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisolone	Rituximab: Anti-CD20 monoclonal antibody	[117]
	Cyclophosphamide: Alkylating agent, inhibits protein synthesis by DNA and RNA crosslinking
	Hydroxydaunorubicin: Inhibits DNA replication and cell production
	Oncovin: Vinca alkaloid, microtubule-disrupting agent. Prednisolone: Suppression of migration of polymorphonuclear lymphocytes and reversal of increased capillary permeability
Ofatumumab; Alemtuzumab; Baricitinib	Anti-CD20 monoclonal antibody; Anti-CD52 monoclonal antibody; Janus kinase inhibitor	[111,118]

Citation: Manrai M, Jha AA, Pachisia AV, Dawra S. Chronic hepatitis B: Is it time for expanded antiviral treatment? World J Virol 2025; 14(3): 103347
URL: https://www.wjgnet.com/2220-3249/full/v14/i3/103347.htm
DOI: https://dx.doi.org/10.5501/wjv.v14.i3.103347

Manrai M, Jha AA, Pachisia AV, Dawra S. Chronic hepatitis B: Is it time for expanded antiviral treatment? World J Virol 2025; 14(3): 103347 [PMID: 41025085 DOI: 10.5501/wjv.v14.i3.103347]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.